<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TOLCAPONE <img border="0" src="../images/pr.gif"/></span><br/>(tol'ca-pone)<br/><span class="topboxtradename">Tasmar<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">anticholinergic (parasympatholytic)</span>; <span class="classification">catecholamine-o-methyltransferase (comt) inhibitor</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg, 200 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Selective inhibitor of catecholamine-O-methyltransferase (COMT). COMT is the enzyme responsible for metabolizing levodopa.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Concurrent administration of tolcapone and levodopa increases the amount of levodopa available to control Parkinson's disease
         by increasing dopaminergic brain stimulation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Idiopathic Parkinson's disease as adjunct to levodopa/carbidopa.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to tolcapone; liver disease; pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of hypersensitivity to other COMT inhibitors (e.g., entacapone, nitecapone); lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Parkinson's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100 mg t.i.d. (max: 200 mg t.i.d.)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food if GI upset occurs.</li>
<li>Give only in conjunction with levodopa/carbidopa therapy.</li>
<li> 				Note: Doses &gt;100 mg t.i.d. are not recommended with moderate to severe liver impairment. 			</li>
<li>Store at 20°25° C (68°77° F) in a tightly closed container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Muscle cramps, orthostatic complaints, fatigue, falling, balance difficulties, hyperkinesia, stiffness, arthritis, hypokinesia. <span class="typehead">CNS:</span> <span class="speceff-common">Dyskinesia, sleep disorder, dystonia, excessive dreaming,</span> somnolence, confusion, dizziness, headache, hallucination, syncope, paresthesias. <span class="typehead">CV:</span> Chest pain, hypotension. <span class="typehead">GI:</span> <span class="speceff-common">Nausea,</span> anorexia, diarrhea, vomiting, constipation, <span class="speceff-life">fulminant liver failure, severe hepatocellular injury</span>, dry mouth, abdominal pain, dyspepsia, flatulence. <span class="typehead">Respiratory:</span> URI, dyspnea, sinus congestion. <span class="typehead">Skin:</span> Sweating. <span class="typehead">Urogenital:</span> UTI, urine discoloration, micturition disorder. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Will increase <b>levodopa</b> levels when taken simultaneously; <span class="classification">cns depressants</span> may cause additive sedation; do not give with non-selective <span class="classification">maoi</span>s <b>(isocarboxazid,</b> <b>phenelzine,</b> <b>or tranylcypromine furazolidone,</b> <b>linezolid,</b> <b>procarbazine).</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract, bioavailability 65%; food decreases bioavailability. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Distribution:</span> &gt;99% protein bound. <span class="typehead">Metabolism:</span> Extensively metabolized by COMT and glucuronidation. <span class="typehead">Elimination:</span> 60% excreted in urine, 40% in feces; clearance is reduced by 50% in patients with moderate cirrhotic liver disease. <span class="typehead">Half-Life:</span> 23 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor liver functions monthly for first 3 mo, every 6 wk for the next 3 mo, and periodically thereafter.</li>
<li>Monitor PT and INR carefully when given concurrently with warfarin.</li>
<li>Monitor carefully for and immediately report S&amp;S of hepatic impairment (e.g., jaundice, dark urine).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not engage in hazardous activities until response to drug is known. Avoid use of alcohol or sedative drugs while on tolcapone.</li>
<li>Rise slowly from a sitting or lying position to avoid a rapid drop in BP with possible weakness or fainting.</li>
<li>Nausea is a common possible adverse effect especially at the beginning of therapy.</li>
<li>Do not suddenly stop taking this drug. Doses must be gradually reduced over time.</li>
<li>Notify physician promptly about any of following: Increased loss of muscle control, fainting, yellowing of skin or eyes, darkening
            of urine, severe diarrhea, hallucinations.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>